Long-term outcome, after first line intensified high-dose sequential (i-HDS) chemotherapy, was evaluated in 46 patients, aged р65 years, with advanced low-grade lymphoma. Seventeen patients had small lymphocytic lymphoma (SLL), 29 had follicular lymphoma (FL), 10 of them with histologic transformation. I-HDS included: (1) tumor debulkying, by 2 APO+2 DHAP courses; (2) sequential administration of high-dose (hd) etoposide, methotrexate, and cyclophosphamide, followed by peripheral blood progenitor cell (PBPC) harvest; (3) hd-mitoxantrone + melphalan with PBPC autograft. Ten FL patients had their PBPC immunologically purged ex vivo. There were two treatment-related deaths; five FL patients had short-lasting response followed by disease progression, five SLL reached a stable PR; overall, 34 patients (74%) reached CR. At a median follow-up of 4.3 years, the estimated 9-year OS and EFS were 84% and 45%, respectively. No significant differences were observed in the OS among patients at low, intermediate or high IPI score, with an estimated OS projection of 95%, 78%, and 75%, respectively. FL had longer survival without evidence of residual disease (9-year EFS: 59%) as compared to SLL patients (8.8-year EFS: 17%); however, both groups had prolonged survival and no need of salvage treatment, as shown by the time to disease progression curve, projected to 66% and 62% for SLL and FL, respectively. The results indicate that hdapproach in low-grade lymphoma: (1) is associated with longer progression-free survival as compared to conventional therapies; (2) may imply higher tumor mass reduction in FL as compared to SLL patients; (3) offers long life expectancy, with potential survival benefits at least for patients at intermediate/high IPI score. Leukemia (2000) 14, 740-747.
Introduction
High-dose chemotherapy and autograft have been recently regarded with increasing interest for the treatment of lowgrade lymphoma. 1 This therapeutic approach has been mainly employed in follicular subtypes, although it has sometimes been considered for lymphocytic lymphoma and chronic lymphocytic leukemia. 2, 3 These studies were based on the assumption that extensive tumor reduction might also be pursued in low-grade lymphoma, with the aim of improving life expectancy and possibly achieving disease eradication.
For a long time, an indolent disease course along with relatively low chemosensitivity discouraged a wide use of intensive treatments in low-grade lymphoma. The pioneer work of the Dana Farber group, reporting for the first time the possibility of reducing minimal residual disease (MRD) under the detection level of PCR-based molecular analysis, gave the necessary spur to these trials. 4 Those data were essentially related to follicular lymphoma patients receiving autologous transplantation with ex vivo purged bone marrow cells. In those cases, a negative PCR was associated with a better disease-free survival, compared to PCR-positive patients. 5 A negative PCR-based MRD was also reported in some patients with chronic lymphocytic leukemia. 6 Subsequently other groups were able to reproduce the initial findings of the Dana Farber group using not just bone marrow, but rather circulating peripheral blood progenitor cells (PBPC). [7] [8] [9] In spite of consistent and encouraging data obtained by molecular studies, a definite clinical indication to the aggressive approach is presently lacking. 10 In fact, all trials carried out so far are very heterogeneous and do not bring about conclusive results. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] First, they considered patient populations at various stage of disease, such as multiple relapse or early progression or even disease onset. Moreover, long-term outcome analysis following an appropriately long follow-up has never been reported. Lastly, analysis on the clinical outcome of different low-grade subtypes treated with the same highdose chemotherapy schedule is not available. Thus, the precise role of high-dose chemotherapy and autograft in the management of low-grade lymphoma still remains uncertain.
In the present study we show data from long-term followup of a series of patients with low-grade lymphoma, including small lymphocytic and follicular subtypes, treated upfront with an intensive high-dose approach. All patients received a modified version of the HDS scheme originally designed by Gianni's group in Milan for poor prognosis diffuse large cell lymphoma, appropriately tailored for indolent histologies. 25, 26 Patients were followed from a minimum of 2 years up to 9 years. Aims of the study were: (1) to assess clinical response of both small lymphocytic and follicular lymphoma subgroups following an upfront intensive treatment; (2) to evaluate the long-term outcome, in terms of event-free and overall survival, of advanced-stage low-grade lymphoma patients managed with an intensive approach since disease presentation.
Patients and treatment plan

Patient characteristics
Between December 1992 and December 1997, 46 patients with biopsy-proven diagnosis of low-grade NHL received a high-dose chemotherapy program as front-line therapy. Histologic examination was supplemented by immunophenotypic analysis if adequate bioptic material was available. Eligibility criteria to enter the study protocol included: (1) histologic diagnosis of lymphocytic or follicular lymphoma; (2) age between 18 and 65 years; (3) Ann Arbor stage III-IV associated with at least one adverse prognostic factor, including: high LDH, symptomatic disease, bulky disease with venous or organ compression, poor performance status, evidence of histologic transformation on biopsy samples; (4) absence of meningeal involvement; (5) negative tests for HCV-HBsAg-HIV; (6) no other associated neoplasia and no previous cytotoxic or radiation therapy. Patients had to give written informed consent prior to entering the high-dose treatment program. Overall, i-HDS was delivered to 46 consecutive patients, aged less than 65 years, requiring undelayed cytoreductive therapy due either to high tumor burden (19 patients) or to symptoms related to local compression (17 patients) or to signs of histologic transformation (10 patients). Main patient characteristics are summarized in Table 1 . Clinical prognostic features were defined according to the International Prognostic Index score. 27 Histologic classification identified 17 patients with small lymphocytic lymphoma (SLL) and 29 with follicular lymphoma (FL). The SLL subgroup included 10 patients with lymphocytic lymphoma or chronic lymphocytic leukemia, six with monocytoid/marginal zone lymphoma and one with lymphoplamocytoid lymphoma; among 29 FL patients, 10 had either transformed or discordant histology.
Treatment plan
The schedule was developed by modification of the previously described high-dose sequential (HDS) chemotherapy regimen. The original HDS regimen includes the sequential administration at 15-20-day intervals of high-dose (hd) cyclophosphamide (CY) given at 7 g/m 2 i.v., with peripheral blood progenitor cell (PBPC) harvest at hemopoietic recovery, hdmethotrexate (8 g/m 2 ) plus vincristine (2 mg i.v.), hd-etoposide (VP16) at 2 g/m 2 , and then myeloablative treatment with PBPC autograft. 25 The main modification was an intensive debulkying prior to the hd-phase including two complete, full-dose APO courses, accounting for a total of four doxorubicin administrations at 75 mg/m 2 . 28 Patients not achieving CR after APO received two additional DHAP courses. 29 In the hdphase, the CY/VP16 sequence was inverted, in order to schedule PBPC harvest at the end of the hd-scheme. In addition, a chemotherapy-free interval of 30 days was introduced prior to hd-CY, in order to allow adequate bone marrow recovery for an optimal progenitor cell mobilization. 26, 30 In the chemotherapy-free interval, a total of three hd-dexamethasone courses (dexamethasone at 40 mg/day for 4 consecutive days) were administered every 10 days. The combined administration of hd-mitoxantrone and hd-melphalan (L-PAM) was used as conditioning regimen in all patients. 31 Mitoxantrone was given i.v. at 60 mg/m 2 in three divided doses of 1 h each every 2 h on day −5; L-PAM was given i.v. at 180 mg/m 2 in In the lymphocytic subgroup, 10 patients had lymphocytic lymphoma or chronic lymphocytic leukemia, six had monocytoid/marginal lymphoma and one had lymphoplasmocytoid lymphoma; in the follicular subgroup, 10 patients had transformed or discordant histology.
Leukemia three divided doses of 30 min each every 2 h on day −2; PBPC were reinfused on day 0. G-CSF (filgrastim) was given at 5 g/kg daily following CY, VP16, and autograft, until myelopoietic recovery. 32 Radiotherapy was given on bulky sites approximately 2 months after autograft. The whole i-HDS is summarized in Figure 1 .
Patients were considered eligible for PBPC autograft if a minimum of 5 × 10 6 CD34 + /kg or 30 × 10 4 CFU-GM/kg were collected. For values ranging between 2 and 5 × 10 6 CD34 + /kg or 5 and 30 × 10 4 CFU-GM/kg, additional BM cells were combined to leukapheresis collection. Patients without detectable mobilization were candidates to autograft with BM cells only, provided that at least 2 × 10 4 marrow CFU-GM/kg could be collected. In the FL subgroup, 10 patients (eight FL with PCR positive harvests and two with transformed histology) had their grafted material immunologically purged ex vivo using immunomagnetic beads and a cocktail of monoclonal antibodies anti CD19, CD20, CD22, CD23 (Baxter, Deerfield, IL, USA), as already described. 33 Overall, nine patients (six SLL and three FL) did not complete the final autograft phase due to the following reasons: (1) for SLL subgroup: patient refusal, 2; BM disease persistence, 3; toxic death, 1; (2) for FL subgroup: disease progression, 2; discovery of concurrent neoplasia (gastric cancer) at pre-autograft restaging, 1. Among 37 patients undergoing autograft, Figure 1 i-HDS regimen schedule. 
Response assessment
Clinical response was assessed by full restaging at 2 months after autograft and thereafter at 3-month intervals for the first year and at 6-month intervals for the subsequent years. Complete response (CR) was defined by the absence of any clinical sign of disease, while partial remission (PR) was defined by a 50% or more tumor reduction. All patients started on treatment were considered evaluable for response assessment. Survival duration was measured from therapy start to date of death or last follow-up alive; event-free survival was calculated from therapy start to the first adverse event, ie failure to reach CR, relapse, secondary malignancy, treatment-related or disease-related death, or last follow-up. Time to disease progression was calculated from therapy start through any eventual salvage treatment for either disease recurrence or secondary malignancy or to death due to any cause, or last followup. The closing date for analysis was 30 June 1999. Overall survival (OS), event-free survival (EFS) and time to disease progression (TDP) curves were calculated by the Kaplan and Meier method. 34 Differences in OS, EFS or TDP according to IPI score (low vs intermediate vs high) or to histology (SLL vs FL) were calculated using the log-rank test. The follow-up had to be discontinued in four patients due to the following reasons: one FL patient maintained his heavy smoking habit (Ͼ60 cigarettes per day) after autograft; 3 years later he developed a laryngeal neoplasia while in continuous CR of his hematological disease and since then he was excluded from any further follow-up; one SLL patient had a previous history of ethanol addiction; he went back to heavy alcohol consumption 3 years after treatment completion and was then lost at follow-up; two more patients of the SLL subgroup, one with monocytoid lymphoma and one with CLL, underwent allogeneic PBSC transplantation from a HLA-identical sibling, while in PR following HDS and at disease relapse 2 years since HDS, respectively. They are presently alive; however, they were excluded from the long-term analysis since the time of allogeneic transplantation.
Results
Toxicity and feasibility of i-HDS schedule
There were two deaths during treatment delivery: one patient with SLL, receiving warfarin for deep vein thrombosis at presentation, had a fatal CNS hemorrhage in spite of normal platelet count prior to the hd-phase; a second patient with follicular lymphoma died of CNS hemorrhage while in persistent thrombocytopenia following autograft performed with BM cells. This was one of the two patients displaying poor mobilization, where we could not employ PBPC for autograft. Other toxicities recorded during HDS delivery were fever, few documented infectious episodes and grade 3-4 oral mucositis.
Main hematologic and extrahematologic toxicities are summarized in Table 2 .
Response to i-HDS
Marked tumor regression was observed in most patients and 34 (74%) reached complete remission (CR). As shown in Table 3 , CR was achieved by 11 patients (65%) of the SLL subgroup, and 23 (79%) of the FL subgroup; five more follicular patients had a short-lasting response soon followed by tumor progression and died within few months; four of these patients had transformed histology. In the SLL subgroup, five patients were classified in PR after i-HDS due to persistence of limited marrow disease, with complete regression of any other disease sign or symptom.
Long-term outcome
With a median follow-up of 4.3 years, the estimated 9-year OS and EFS for the entire group were 84% and 45%, respectively ( Figure 2 ). The long-term outcome was also evaluated according to the IPI score: patients with score 0-1 (low risk) had a longer survival as compared to patients with score 2-3 (intermediate risk) and score 4 (high risk), with an estimated OS projection of 95%, 78%, and 75%, respectively; however, the differences did not reach statistical significance (Figure 3) . No significant differences were also seen among the three groups in terms of EFS (data not shown).
There was no statistically significant difference in OS curves between SLL and FL subgroups, with estimated 94% projection at 8.8 years and 79% at 9.3 years, as shown in Figure 4 . By contrast, a significant difference was observed in the longterm EFS. Indeed, a lower, though not significant, proportion of SLL patients reached CR compared to FL patients. In addition, four SLL patients in CR had disease recurrence; one patient developed symptomatic myelodysplasia at 16 months since autograft while in CR; overall five evaluable SLL patients are presently alive in continuous CR. In the FL subgroup, four out of 23 patients in CR relapsed, within 2-6 years since autograft; one more patient in CR was diagnosed as bearing myelodysplasia at 1 year from autograft; the myelodysplasia progressed to acute leukemia within 1 year. The patient is now in CR of her second tumor at 16 months following a second salvage autograft. Overall, the EFS curve is projected to 59% at 9.3 years in the FL subgroup and to 17% at 8.8 years in the SLL subgroup (P Ͻ 001), as shown in Figure 5 . In order to further evaluate how long patients did not require further treatment after initial i-HDS, a time to disease progression (TDP) curve was calculated. Curves were similar in both subgroups, with a TDP projection of 66% and 62% for SLL and FL subgroups, respectively, as shown in Figure 6 .
Discussion
This study was aimed at evaluating the long-term outcome of 46 low-grade lymphoma patients aged Ͻ60 years receiving upfront high-dose chemotherapy and PBPC autograft. In spite of advanced-stage presentation, response to treatment was very good and the overall survival was long, projecting 84% of patients alive at 9 years. The long-term follow-up showed that about two-thirds of the patients of both SLL and FL subtypes survived without requirement of any further treatment. However, FL patients had a higher chance of survival without evidence of disease persistence than SLL patients, suggesting that hd-chemotherapy may yield a more extensive cytoreduction in FL than in SLL patients.
Several aspects distinguish our study from previous reports. First, the treatment schedule was particularly intense, including a prolonged debulkying phase prior to PBPC harvest, in order to collect as least contaminated hemopoietic cells as possible. In addition, all patients received the same high-dose program as first-line treatment. All patients presenting with newly diagnosed low-grade lymphoma received i-HDS if they had to be immediately treated due to one of the following
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Figure 3
Overall survival of low, intermediate and high risk subgroups, identified by the International Prognostic Index score. No statistically significant differences were observed among the three curves.
Figure 4
Overall survival curves of lymphocytic (SLL) and follicular (FL) subgroups. Median follow-up of censored patients: 3.7 and 5 years for SLL and FL, respectively. No statistically significant difference was observed between the two curves.
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Figure 5
Event-free survival curves of lymphocytic (SLL) and follicular (FL) subgroups. Events were: failure to achieve CR, relapse, secondary neoplasia, death due to treatment-related causes or to disease. Median follow-up of censored patients: 3.4 and 5 years for SLL and FL, respectively. The difference between the two curves showed statistical significance (P Ͻ 0.01, log-rank test).
Figure 6
Time to disease progression curves of lymphocytic (SLL) and follicular (FL) subgroups. Progression was defined by any salvage treatment required for disease progression or secondary tumors as well as by any toxic or disease-related death. Median follow-up of censored patients: 3.5 and 5.1 years for SLL and FL, respectively. No statistically significant difference was observed between the two curves.
reasons: (1) high tumor burden; (2) symptoms related to local compression; (3) evidence of histologic transformation. Finally, the prolonged follow-up allowed collection of reliable data not only on response to treatment but also on longterm outcome.
The program was globally well tolerated. Unfortunately there were two fatal events, both due to CNS bleeding: the first patient died prior to the high dose phase in spite of normal platelet values; the other patient had persistent severe thrombocytopenia following autograft, performed with bone marrow cells. This adverse event further supports a preferential use of PBPC in these patients in order to minimize infectious and hemorrhagic risks related to prolonged pancytopenia. 35, 36 There were few infectious complications, with incidence and severity analogous to those previously reported in HDS programs. 25, 35 Despite the intensive treatment, PBPC could be harvested in sufficient amounts to perform autograft in most patients, as already reported in a previous study. 30 This is an important aspect of our program. Indeed, a non-negligible stem cell pool depletion, potentially precluding progenitor cell harvest, has been reported with programs based on CHOP intensification. 37 The risk of second tumor does not seem to be particularly high. So far, two patients have developed myelodysplasia, which has rapidly progressed to acute leukemia in one patient; a heavy-smoker developed laryngeal cancer. Hence, the observed incidence of secondary tumors was similar or even lower, than that reported by other studies, although a more prolonged follow-up is still required. 38, 39 It should be outlined that our approach based on hd-chemotherapy at disease onset may lower the risk of secondary malignancies, which is often associated with heavy and prolonged pretreatments. In addition, total body irradiation avoidance might have reduced the tumorigenic risk of our program.
The i-HDS had a high antitumor activity as shown by a 74% CR rate. In a wide retrospective SWOG study, CR rates ranged between 57 and 63% in stage III-IV low-grade NHL treated at disease onset with doxorubicin-based chemotherapy. 40 Thus, HDS offers better results in terms of tumor response as compared to that study, which can be regarded as the comparative standard for any innovative treatment. The high response rate is probably due to the prolonged debulkying strategy with APO, DHAP and then VP16-MTX-CY, before the final autograft. Most patients with FL responded to treatment, with 79% CR. This CR rate is definitely high if one takes into account that transformed histologies were also included, and it lies among the highest CR rates ever reported in advanced FL patients using either high-dose or conventional or fludarabinebased regimens. [17] [18] [19] [20] [21] [22] [23] [24] [41] [42] [43] [44] High tumor reduction was observed among SLL patients as well, with a 65% CR rate. Also in this subgroup, the observed CR rate was satisfactory and superior to the best results reported with non-myeloablative approaches. 45, 46 SLL patients who did not achieve CR were in all cases unable to get rid of their bone marrow infiltration. Thus, bone marrow clearing seems the most difficult task to accomplish in SLL patients.
Disease response was sustained in both FL and SLL subgroups. A good proportion of patients had long-term relapsefree survival. Other patients, most in the SLL subgroup, survived with persistent marrow disease but no evidence of progression. These features account for the long TDP, with a median TDP not yet reached at a median follow-up of 5.1 and 3.5 years in FL and SLL patients, respectively. The results confirm at an appropriately long follow-up, previous observations in low-grade lymphoma patients receiving upfront hdchemotherapy. [17] [18] [19] [20] [21] [22] These patients have substantial benefit from the hd-approach, with a prolonged survival and no need of salvage therapies when compared to patients managed with a conventional approach. [40] [41] [42] [43] [44] [45] [46] Most FL patients are long-term event-free survivors. There was a relapse at 6 years after autograft. This confirms the need for a long follow-up before drawing definite conclusions. Nevertheless, given the prolonged survival without evidence of disease or any severe treatment-related complication, a possible cure can be hoped, at least in a fraction of FL patients. On the contrary, only few SLL patients had long-term disease-free survival, in spite of long symptom-free survival; none of these patients received ex vivo purged PBPC, while 745 this treatment was employed in a few FL patients. However, by the time of PBPC harvest many more patients in the SLL group had persistent marrow involvement with respect to the FL group. Moreover, PCR negativity is often observed in FL patients, whereas this is only seldom achieved in hd-treated SLL patients. [7] [8] [9] 44, 47, 48 Taken together, these data argue against a curative potential of the hd-approach in SLL forms, while this goal seems possible in FL patients.
At present, there is no evidence that the hd-approach might improve overall life expectancy of low-grade lymphoma patients. [1] [2] [3] 10 In our study, the overall survival was satisfactory, with a 84% projection at 9 years. In the large SWOG study on conventionally treated, advanced-stage patients, median life expectancy was 6.5 years. 40 Although our median follow-up of 4.3 years does not allow a direct comparison with that study, the 84% projection is suggestive of an improved survival using i-HDS. The results in terms of survival were highly satisfactory even when patients were subdivided according to the IPI score. There was a prevalence of patients with low and intermediate risk, and only few patients at high risk. This is in line with results reported in the original works dealing with IPI in conventionally treated patients. 27, 49 However, our OS results seem superior to the ones reported in those studies independently by the prognostic category considered. 27, 49 Several novel approaches are now becoming available for the treatment of low-grade lymphoma. 2 It is likely that these new therapeutic options will significantly improve the clinical outcome in low-grade lymphoma. We feel that our results are very promising, suggesting that the hd-approach should be considered for any future comparison with new strategies. Moreover, the hd-approach might be successfully associated with some of the novel non-chemotherapeutic options, such as the anti-CD20 chimeric monoclonal antibody Rituximab. 50, 51 In fact, preliminary results using the HDS program supplemented with Rituximab showed that this combination is feasible and highly effective in terms of both tumor reduction and in vivo purging effect. 52 Future studies will assess whether the association of Rituximab to HDS is a real progress towards disease eradication in low-grade lymphoma.
